Overview

Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States

Status:
TERMINATED
Trial end date:
2025-06-18
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety of SRP-9004.
Phase:
PHASE1
Details
Lead Sponsor:
Sarepta Therapeutics, Inc.